Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer

被引:3
|
作者
Zhang, Yue [1 ]
Lv, Lianqiu [1 ]
Zheng, Renjing [1 ]
Xie, Rong [1 ]
Yu, Yuanhang [1 ]
Liao, Han [1 ]
Chen, Jianying [2 ]
Zhang, Bo [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Breast & Thyroid Surg, Wuhan 430022, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, Wuhan 430022, Peoples R China
基金
中国国家自然科学基金;
关键词
TNBC; miR-26a-5p; DNA damage; HRD; Cisplatin; Synthetic lethal; DNA-REPAIR; CISPLATIN; DAMAGE; PROLIFERATION; MECHANISMS; APOPTOSIS; DATABASE; CELLS;
D O I
10.1186/s13058-023-01663-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundDNA damage and DNA damage repair (DDR) are important therapeutic targets for triple-negative breast cancer (TNBC), a subtype with limited chemotherapy efficiency and poor outcome. However, the role of microRNAs in the therapy is emerging. In this study, we explored whether miR-26a-5p could act as BRCAness and enhance chemotherapy sensitivity in TNBC.MethodsQuantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the expression of miR-26a-5p in breast cancer tissues and cell lines. CCK-8 was used to measure drug sensitivity in concentration gradient and time gradient. Comet assay was used to detect DNA damage. Flow cytometry was performed to examine apoptosis. Moreover, we used western blot and immunofluorescence to detect biomarkers. Luciferase reporter assay was performed to verify the combination of miR-26a-5p and 3'UTR of target gene. Hormone deprivation and stimulation assay were used to validate the effect of hormone receptors on the expression of miR-26a-5p. Chromatin immunoprecipitation (ChIP) assays were used to verify the binding sites of ER-a or PR with the promoter of miR-26a-5p. Animal experiments were performed to the effect of miR-26a-5p on Cisplatin treatment.ResultsThe expression of miR-26a-5p was significantly downregulated in TNBC. Overexpressing miR-26a-5p enhanced the Cisplatin-induced DNA damage and following apoptosis. Interestingly, miR-26a-5p promoted the expression of Fas without Cisplatin stimulating. It suggested that miR-26a-5p provided a hypersensitivity state of death receptor apoptosis and promoted the Cisplatin sensitivity of TNBC cells in vitro and in vivo. Besides, miR-26a-5p negatively regulated the expression of BARD1 and NABP1 and resulted in homologous recombination repair defect (HRD). Notably, overexpressing miR-26a-5p not only facilitated the Olaparib sensitivity of TNBC cells but also the combination of Cisplatin and Olaparib. Furthermore, hormone receptors functioned as transcription factors in the expression of miR-26a-5p, which explained the reasons that miR-26a-5p expressed lowest in TNBC.ConclusionsTaken together, we reveal the important role of miR-26a-5p in Cisplatin sensitivity and highlight its new mechanism in DNA damage and synthetic lethal.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] Transcriptionally regulated miR-26a-5p may act as BRCAness in Triple-Negative Breast Cancer
    Yue Zhang
    Lianqiu Lv
    Renjing Zheng
    Rong Xie
    Yuanhang Yu
    Han Liao
    Jianying Chen
    Bo Zhang
    Breast Cancer Research, 25
  • [2] The oncogenic role of miR-150-5p in triple-negative breast cancer
    Sugita, Bruna M.
    Zabala, Yara
    Fonseca, Aline
    Almeida, Rodrigo
    Gusev, Yuriy
    Boca, Simina
    Cavalli, Iglenir J.
    Ribeiro, Enilze M.
    Cavalli, Luciane R.
    CANCER RESEARCH, 2017, 77
  • [3] MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer
    Ma, Sugang
    Wei, Hui
    Wang, Chunyan
    Han, Jixia
    Chen, Xiumin
    Li, Yang
    CELLULAR & MOLECULAR BIOLOGY LETTERS, 2021, 26 (01)
  • [4] MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer
    Sugang Ma
    Hui Wei
    Chunyan Wang
    Jixia Han
    Xiumin Chen
    Yang Li
    Cellular & Molecular Biology Letters, 2021, 26
  • [5] Hsa-miR-105-5p acts as an oncogene in triple-negative breast cancer
    Qian, Da
    Zhou, Tao
    Xiong, Hanchu
    Xu, Yuhao
    Qiu, Jie
    Wu, Yihao
    Hong, Weimin
    Meng, Xuli
    CHINESE MEDICAL JOURNAL, 2023, 136 (24) : 3022 - 3024
  • [6] Hsa-miR-105-5p acts as an oncogene in triple-negative breast cancer
    Qian Da
    Zhou Tao
    Xiong Hanchu
    Xu Yuhao
    Qiu Jie
    Wu Yihao
    Hong Weimin
    Meng Xuli
    中华医学杂志(英文版), 2023, 136 (24)
  • [7] Validation of a BRCAness test to select for targeted therapies in triple-negative breast cancer
    Gross, E.
    Brunet, T.
    Napieralski, R.
    Singer, T.
    Aubele, M.
    Schmitt, M.
    Meindl, A.
    Lips, E.
    Kiechle, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 54 - 54
  • [8] BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Nishimiya, Hiroshi
    Tanaka, Youko
    Minatani, Naoko
    Kikuchi, Mariko
    Shida, Akiko
    Waraya, Mina
    Katoh, Hiroshi
    Enomoto, Takumo
    Sengoku, Norihiko
    Kajita, Sabine
    Hoffman, Robert M.
    Watanabe, Masahiko
    PLOS ONE, 2016, 11 (12):
  • [9] BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Sengoku, Norihiko
    Waraya, Mina
    Nishimiya, Hiroshi
    Katoh, Hirozhi
    Kikuchi, Mariko
    Minatani, Naoko
    Teraoka, Saeko
    Enomoto, Takumo
    Sato, Takeo
    Masahiko, Masahiko
    CANCER RESEARCH, 2015, 75
  • [10] BRCAness by MLPA is clinically useful for tailored treatment in triple-negative breast cancer
    Ishikawa, Takashi
    Narui, Kazutaka
    Yamada, Akimitsu
    Sugae, Sadatishi
    Ichikawa, Yasushi
    Oba, Mari S.
    Teraoka, Saeko
    Kida, Kumiko
    Shima, Hidetaka
    Endo, Itaru
    CANCER RESEARCH, 2015, 75